Market Overview

UPDATE: Morgan Stanley Reiterates On Incyte On ASCO Abstracts


In a report published Thursday, Morgan Stanley analyst David Friedman reiterated an Underweight rating on Incyte (NASDAQ: INCY), but removed the $14.00 price target.

In the report, Morgan Stanley noted, “OS and PFS data trended together and seem to be generating a clinically meaningful pt benefit. While we have not seen the K-M survival curves, the subgroup data at 3 and 6 months suggest a solid OS curve for the drug if replicated in larger Ph 3 trials, despite a low response rate (likely a smaller issue).”

Incyte closed on Wednesday at $55.90.

Latest Ratings for INCY

Jan 2021Truist SecuritiesInitiates Coverage OnBuy
Nov 2020Morgan StanleyMaintainsEqual-Weight
Nov 2020BMO CapitalMaintainsMarket Perform

View More Analyst Ratings for INCY
View the Latest Analyst Ratings


Related Articles (INCY)

View Comments and Join the Discussion!

Posted-In: David Friedman Morgan StanleyAnalyst Color Price Target Analyst Ratings

Latest Ratings

TSLAJP MorganMaintains125.0
INTCTruist SecuritiesMaintains64.0
FBTruist SecuritiesMaintains320.0
AAPLCowen & Co.Maintains153.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at